Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection
- 98 Downloads
Background and Objectives
The efficacy of < 12 weeks of hepatitis C virus (HCV) treatment in patients co-infected with HCV and human immunodeficiency virus type 1 (HIV-1) has not been established. We assessed the efficacy and safety of ledipasvir–sofosbuvir for 8 weeks in HCV mono-infected and HCV/HIV-1 co-infected patients.
We enrolled patients mono-infected with genotype 1 HCV or co-infected with HCV and HIV-1 who were HCV treatment-naive and did not have cirrhosis. HCV/HIV-1 co-infected patients were either not receiving antiretroviral treatment and had a CD4 T-cell count > 500 cells/mm3 or were receiving a protocol-approved antiretroviral regimen for ≥ 8 weeks (or ≥ 6 months for abacavir-containing regimens) and had HIV-1 RNA < 50 copies/mL and a CD4 T-cell count > 200 cells/mm3. Patients received ledipasvir–sofosbuvir (90/400 mg) once daily for 8 weeks. The primary efficacy endpoint was sustained virologic response 12 weeks after treatment discontinuation (SVR12).
The SVR12 rate was 100% (67/67) for HCV mono-infected patients and 97% (57/59) for HCV/HIV-1 co-infected patients. Two patients relapsed by the week 4 post-treatment visit. Overall, the most common adverse events were headache (52%) and upper abdominal pain (26%). There were no serious adverse events or treatment discontinuations due to adverse events. No HCV/HIV-1 co-infected patients receiving antiretroviral treatment experienced HIV virologic rebound, and no clinically meaningful changes in CD4 T-cell counts were observed in any co-infected patient.
Non-cirrhotic, treatment-naive patients with genotype 1 HCV mono-infection and HCV/HIV-1 co-infection achieved high rates of SVR12 with 8 weeks of treatment with ledipasvir/sofosbuvir.
ClinicalTrials.gov identifier: NCT02472886.
Writing assistance was provided by Tiffany DeSimone, PhD, of BlueMomentum, an Ashfield Company, part of UDG Healthcare plc, and was supported and paid for by Gilead Sciences, Inc.
KK, AO, ES, and DB contributed to the study concept and design. All investigators collected data, and all authors contributed to data analysis/interpretation and to drafting or critically revising the manuscript. All authors approved the final version of the article.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflicts of Interest
Vasily Isakov has served on advisory committees or review panels for AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co., R-PHARM, and Vertex Pharmaceuticals. He has also served as a consultant for Bristol-Myers Squibb and Merck & Co., and on speakers’ bureaus for Bristol-Myers Squibb, Janssen Pharmaceuticals, R-PHARM, and Merck & Co. Kathryn Kersey, Sophia Lu, Anu Osinusi, Evguenia Svarovskaia, and Diana M. Brainard are employees and stockholders in Gilead Sciences. Riina Salupere reports personal fees from MSD/Merck, AbbVie, Jannsen, and grants from Intercept outside of the submitted work. Elena Orlova-Morozova has served as a speaker for Janssen-Cilag. Konstantin Zhdanov has served as an investigator for BMS, a speaker and advisor for Abbott, and as an investigator, speaker, and advisor for Gilead, AbbVie, Biocad, Janssen, MSD, Novartis, Roche, and R-Pharm. Natalia Gankina and Viacheslav Morozov have no discloses to declare.
This phase IIIb study (NCT02472886) was sponsored by Gilead Sciences.
- 5.Korolevskaya LB, Shmagel KV, Saidakova EV, Shmagel NG, Slobodchikova SV, Chereshnev VA. Effect of hepatitis c virus coinfection on the content of CD4(+) and CD8(+) T Cell subpopulations in HIV-infected patients receiving antiretroviral therapy. Bull Exp Biol Med. 2016;161(2):281–3.CrossRefPubMedGoogle Scholar
- 8.Lam AM, Murakami E, Espiritu C, Steuer HM, Niu C, Keilman M, et al. PSI-7851, a pronucleotide of beta-D-2’-deoxy-2’-fluoro-2’-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother. 2010;54(8):3187–96.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Gilead Sciences, Inc. HARVONI (ledipasvir and sofosbuvir) prescribing information. Foster City: Gilead Sciences, Inc.; 2016.Google Scholar
- 11.Gilead Sciences International Ltd. HARVONI (ledipasvir/sofosbuvir) summary of product characteristics. Cambridge: Gilead Sciences International Ltd; 2016.Google Scholar
- 18.Ingiliz P, Christensen S, Kimhofer T, Hueppe D, Lutz T, Schewe K, et al. Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-mono-infected and HIV-HCV co-infected individuals—results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis. 2016;63(10):1320–4.CrossRefPubMedGoogle Scholar
- 19.Ain D, Wolfe P, Weissman M, et al. Ledipasvir/sofosbuvir for 8 weeks in patients co-infected with HCV and HIV-1. In: Presented at HEP DART, December 2015, Wailea, HI.Google Scholar
- 21.Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97.CrossRefPubMedGoogle Scholar
- 22.Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2(8):e319–27.CrossRefPubMedGoogle Scholar